The YARS2 antibody is designed to target the mitochondrial tyrosyl-tRNA synthetase 2 (YARS2), an enzyme critical for mitochondrial protein synthesis. YARS2 belongs to the family of aminoacyl-tRNA synthetases (aaRSs), which catalyze the attachment of specific amino acids to their cognate tRNAs during translation. Unlike its cytoplasmic counterpart (YARS1), YARS2 functions exclusively in mitochondria, where it charges mitochondrial tRNA-Tyr with tyrosine, ensuring fidelity in mitochondrial DNA-encoded protein production. Mutations in the YARS2 gene are linked to mitochondrial disorders, such as myopathy, lactic acidosis, and sideroblastic anemia (MLASA), a rare autosomal recessive condition. These mutations impair mitochondrial translation, leading to respiratory chain dysfunction and cellular energy deficits. The YARS2 antibody serves as a vital tool in research to study YARS2 expression, localization, and dysfunction in disease models. It is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate mitochondrial pathologies, validate gene-editing outcomes, or explore therapeutic strategies targeting mitochondrial protein synthesis. Its development underscores the growing focus on mitochondrial biology and the role of aaRSs in human diseases, particularly those affecting tissues with high energy demands, such as muscle and nervous systems.